Originally published Wednesday, December 31, 2008 at 6:55 AM
Comments (0)
E-mail article
Print view
Biotech proves defensive against tough 2008 market
Sharp gains in shares of biotechnology heavyweights mitigated the wider sector's decline in 2008. Biotech stocks proved to be one of the safest investments this year, as strong drug sales and the potential for large buyout deals defended the sector from broader market collapse.
AP Business Writer
Sharp gains in shares of biotechnology heavyweights mitigated the wider sector's decline in 2008. Biotech stocks proved to be one of the safest investments this year, as strong drug sales and the potential for large buyout deals defended the sector from broader market collapse.
Biotech products are usually considered lifesaving necessities by patients, and thus not likely to get cut out of a budget because of a weak economy. Furthermore, with no development path paved yet for generic biologics, biotech companies don't face the same competition as their big pharma cousins.
Many of the largest players, including Genentech Inc. and Amgen Inc., ended 2008 up about 23 percent and 24 percent respectively. Vertex Pharmaceuticals Inc. climbed 31 percent, Celgene Corp. 18 percent and HIV drug maker Gilead Sciences Inc. 12 percent. The substantial gains by many large biotechs offset a 16 percent loss by Biogen Idec Inc., a 65 percent loss seen in PDL BioPharma Inc. shares and Amylin Pharmaceuticals Inc.'s 72 percent drop.
The American Stock Exchange's biotechnology index, which includes several bellwether stocks, fell about 22 percent during the year. The broader Dow Jones U.S. biotechnology index shows a gain of 3 percent for the year.
The sector far outperformed the Dow Jones Total Market Index, which is off 40 percent for the year, and the Standard & Poor's 500 index which is down 39 percent.
One industry-wide theme in 2008 was buyout activity. In large part, it helped reverse the previous year's downward slide.
Large pharmaceutical companies continued to shop for big and small biotechs in order to flesh out lagging pipelines of new drugs and grow revenue streams. Biotech companies, whose products generally are made from living cells, also offer some protection against generic competition because currently there is no legal pathway for approval of copies of biotech drugs.
In 2008, Japan's Takeda Pharmaceuticals bought Millennium Pharmaceuticals for $8.8 billion, Eli Lilly & Co. bought ImClone Systems Inc. for $6.5 billion, and analysts expect Roche to eventually buy Genentech Inc., despite having its $43.7 billion offer rejected as too low.
"The need among pharmaceutical companies to acquire smaller companies to fulfill their pipelines, that is not going away," S&P equity research analyst Steven Silver said in a recent interview.
Much of Thousand Oaks, Calif.-based Amgen's rise came from expectations over its future sales potential with the osteoporosis drug denosumab. In June, the company gave investors a sneak peak at study results showing the drug reduced the rate of spinal fractures in postmenopausal women. The company has already asked for FDA approval and analysts have placed denosumab's sales potential at $2 billion annually.
Meanwhile, South San Francisco, Calif.-based Genentech gained on strong sales and continued potential for its key blockbuster cancer drug Avastin. Shares rose following Roche's bid but have since receded to below that $89-per-share offer.
Not all was rosy, however, as safety concerns plagued some in the sector.
Amylin's shares plunged due to questions about the safety of diabetes drug Byetta and the company's next-generation treatment, exenatide LAR. Meanwhile, safety issues of multiple sclerosis drug Tysabri drove shares of Biogen Idec and partner Elan down sharply as well.
Copyright © 2008 The Seattle Times Company
More Business & Technology headlines...
E-mail article
Print view Share:
Digg
Newsvine
![]()
Chase shrugs off loss of CD investors
Sunday Buzz: Expedia, Intelius, Classmates slapped by Senate report
Denny Triangle gains skyline, but tenants slow to come
UPDATE - 04:28 PM
Senate Democrats at odds over health care bill
Your Funds: Money for nothing: Some investors pay for advice they never get

LA Galaxy's David Beckham
Los Angeles Galaxy's David Beckham talks about the upcoming MLS Cup final during after a team practice.
nwjobs

Post a comment

Michelle Goodman blogs about work/life balance.
How to tell your office you're gravely ill
Post a comment
nwautos

Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Craigslist adoption ad: A plea by young mother-to-be? A scam?
- Italian lead prosecutor argues Knox motive was hatred
- Italian prosecutors request life sentence for UW student
- Tugboat sinks on Seattle's waterfront
- Child-support error costs nearly $21,000
- Man shot in chest on E. Union Street in Capitol Hill
- Washington state wines make annual best-of list
- Chase shrugs off loss of CD investors
- Mariners Blog | A Mariners-Tigers swap makes a whole lot of sense for both teams
- Senate vote clears hurdle
234 - Tight Senate vote launches health care over hurdle
119 - Child-support error costs nearly $21,000
117 - Palin excitement builds in Tri-Cities
115 - Vikings easily beat the Seahawks
112 - Prosecutor requests life in prison for Amanda Knox
87 - Cutting through breast-cancer confusion
86 - Game thread
70 - New York terror trials will restore faith in rule of law
52 - Chase shrugs off loss of CD investors
46
- Washington state wines make annual best-of list
- Nonprofits get creative using Twitter and Facebook to make donation easier
- It's possible to recover a life lost to hoarding
- Lynnwood is reinventing itself — again
- Great places to cross-country ski for free (or almost) in the Methow
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Child-support error costs nearly $21,000
- Recipes: Sesame Pork Roast, Sour Cream Mashed Potatoes, Gingerbread with Lemon Sauce and more
- Banff: powder, peaks & purity
- 175 foster kids in Washington get 'forever families'





